 |
Prospector
Profile
201-01
|
| |
| BioPure Corp. |
NAICS |
325414 |
| 11 Hurley Street
Cambridge, MA 02141 |
Description |
Pharmaceuticals Mfg. |
| (617) 234-6500 |
Employees |
86 |
| http://www.biopure.com/ |
Revenue |
(mil) |
2.5560 |
| |
Income |
(mil) |
-36.2820 |
| |
Assets |
(mil) |
14.2500 |
| |
Liability |
(mil) |
4.5860 |
| |
(for the year ended 2007-10-31) |
| |
|
Category:
Audit Concerns
|
| |
|
Event:
Ernst & Young raised substantial doubt about Biopure Corporation's ability to continue as a going concern after it audited the company's financial statements for the year ended October 31, 2007. The auditing firm pointed to the company's recurring losses from operations and lack of sufficient funds to sustain its operations through the end of fiscal 2008. The company posted a net loss of $36,282,000 on total revenues of $2,556,000 for the year ended October 31, 2007, as compared with a net loss of $26,454,000 on total revenues of $1,715,000 in the prior year.
|
| |
|
Intellectual Property:
The Company actively seeks patent protection both in the United States and abroad. The Company filed its initial patent in 1986 in the United States, which has resulted in 5 U.S. patents issued. These patents describe and claim ultra-pure semi-synthetic blood substitutes and methods for their preparation. In total, the Company has 21 U.S. patents granted and 2 applications pending relating to its oxygen therapeutics. The Company has also registed the names Biopure, Hemopure, Oxyglobin and Oxygen Bridge. [SEC Filing 10-K 01-29-08]
|
| |
|
Description:
Biopure engages in the development, manufacture, and marketing of pharmaceuticals, called oxygen therapeutics, that are intravenously administered to deliver oxygen to the body's tissues.
|
| |
|
Officers:
Zafiris G. Zafirelis (Pres., CEO & Dir.); Jane Kober (SVP, Sec. & Gen. Counsel); David A. Butler (Interim CFO); Geoffrey J. Filbey (VP); Barry L. Scott (VP)
|
| |
|
Auditor:
Ernst & Young
|
| |
|
Securities:
Common Stock-Symbol BPUR; Nasdaq;
34,971,087 common shares outstanding as of January 23, 2008.
|
| |
| |
| |
| return to main page |
|
|
